South China Morning Post
Which company could become the Chinese Pfizer? Here are analysts’ top picks
A handful of Chinese biotechnology companies are expected to bring medications to consumers in Europe and the US under their own brand names within the next 10 to 15 years, according to policy and industry analysts. Amid China’s…
View original source — South China Morning Post ↗
Related stories
MarketWatch
PoliticsJun 8, 2026 · 1 min
Trump’s Washington is suddenly moving toward taking stakes in AI companies. Will it actually happen?
MarketWatch
Bloomberg
BusinessJun 5, 2026 · 1 min
AstraZeneca Broadens US Growth Push
Bloomberg
The New York Times
TechnologyJun 9, 2026 · 1 min
OpenAI Tests Investor Appetite for Yet Another Giant I.P.O.
The New York Times
Financial Times
HealthJun 9, 2026 · 1 min
GSK in talks to buy cancer biotech Nuvalent for more than $9bn
Financial Times